Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | H.Nokihara, T. Hida, M. Kondo, Y. Hak Kim, K. Azuma, T. Seto, Y.Takiguchi, M. Nishio, H. Yoshioka, F. Imamura, K.Hotta, S. Watanabe, K. Goto, K. Nakagawa, T. Mitsudomi, N.Yamamoto, H. Kuriki, R. Asabe, T. Tanaka, T. Tamura | ||||||||||||
Title | Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study. | ||||||||||||
|
|||||||||||||
URL | http://meetinglibrary.asco.org/content/167434-176 | ||||||||||||
Abstract Text | J Clin Oncol 34, 2016 (suppl; abstr 9008) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK fusion | lung non-small cell carcinoma | sensitive | Alectinib | Phase III | Actionable | In a Phase III trial, treatment with Alecensa (alectinib) resulted in improved progression-free survival compared to treatment with Xalkori (crizotinib) (HR=0.34) in ALK-positive non-small cell lung cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 9008)). | detail... |